Engineered Extracellular Vesicles for Neuroimmunological Disorder Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for neuroimmunological disorders, such as gliomas and glioblastoma multiforme, are inadequate, with limited clinical efficacy and significant side effects, necessitating the development of more effective and targeted therapeutic approaches.
Innovation Solution
Engineered extracellular vesicles (EVs) capable of targeting cells within the central nervous system, loaded with antigens and adjuvants, induce a humoral immune response, specifically binding to misfolded neuronal proteins, thereby reducing their levels and modulating germinal center responses to improve symptoms associated with neurological disorders.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional treatments (surgery, radiation therapy, chemotherapy) are used for gliomas, then tumor removal or suppression is achieved, but patient survival rate remains low (14-15 months) with significant side effects
Solution Approach 1:
The patent uses engineered extracellular vesicles (EVs) as intermediary carriers to deliver antigens and adjuvants to the central nervous system. These EVs serve as a mediator between the immune system and tumor cells, enabling targeted immunotherapy that avoids the harsh side effects of conventional chemotherapy and radiation while improving treatment efficacy through specific antigen presentation to immune cells
Solution Approach 2:
The patent employs the body's own immune system to fight the tumor by engineering EVs that stimulate endogenous antibody production and immune responses. The engineered EVs carry tumor-associated antigens that trigger the patient's immune system to naturally recognize and attack glioma cells, eliminating the need for externally aggressive treatments and their associated side effects
2Reliability
If dendritic-cell derived exosomes (DEX) are used as immunotherapy, then immune response is stimulated, but clinical efficacy is limited (Phase II trial terminated due to insufficient progression-free survival)
Solution Approach 1:
The patent modifies key parameters of extracellular vesicles by engineering them to carry specific tumor-associated antigens and adjuvants, altering their immunogenicity and targeting capabilities. This parameter change transforms ordinary EVs into highly effective immunotherapeutic agents that can robustly stimulate immune responses and achieve meaningful clinical efficacy, overcoming the limitations of unmodified DEX
Solution Approach 2:
The patent creates composite engineered EVs that combine multiple functional components including tumor-associated antigens, adjuvants, and targeting moieties within a single vesicle structure. This composite approach integrates antigen presentation, immune stimulation, and targeted delivery capabilities, producing a synergistic effect that surpasses the limited efficacy of single-component DEX therapies
3Measurement precision
If engineered EVs with targeting moieties are used, then specific CNS cell targeting is achieved, but device complexity increases
Solution Approach 1:
The patent applies local quality by incorporating targeting moieties at specific locations on the EV surface rather than uniformly modifying the entire structure. This localized modification approach enables precise targeting of CNS cells while maintaining the natural structure and function of the EV, minimizing the increase in overall complexity while achieving high targeting precision
Data Source
AI summary
The present disclosure relates to extracellular vesicles (EVs) that are capable of targeting a cell in the CNS of a subject. Also provided herein are methods for producing the EVs and methods for using the EVs to treat and/or prevent diseases or disorders of the CNS (e.g., neurological disorders).